

PUBLICATION LIST
JACOB A. CANICK
PROFESSOR
DEPT. OF PATHOLOGY

PEER-REVIEWED PUBLICATIONS:

1. Canick, J.A., Purvis, J.L. (1972) The maintenance of mitochondrial size in the rat adrenal cortex zona fasciculata by ACTH. *Exptl. Mol. Pathol.* 16: 79-93.
2. Purvis, J.L., Canick, J.A., Mason, J.I., McCarthy, J.L., Estabrook, R.W. (1973) The lifetime of adrenal cytochrome P-450 as influenced by ACTH. *Ann. N.Y. Acad. Sci.* 212: 319-343.
3. Purvis, J.L., Canick, J.A., Rosenbaum, J.H., Hologgitas, J., Latif, S.A. (1973) Control of cytochrome P-450 in rat testis mitochondria by human chorionic gonadotropin. *Arch. Biochem. Biophys.* 159: 32-38.
4. Purvis, J.L., Canick, J.A., Latif, S.A., Rosenbaum, J.H., Hologgitas, J., Menard, R.H. (1973) Lifetime of microsomal cytochrome P-450 and steroidogenic enzymes in rat testis as influenced by human chorionic gonadotropin. *Arch. Biochem. Biophys.* 159: 39-49.
5. Canick, J.A., Villee, D.B. (1974) The effect of adrenocorticotrophin on protein degradation in rat adrenal and liver. *Biochem. J.* 144: 397-403.
6. Canick, J.A., Ryan, K.J. (1975) The inhibition of 16α -hydroxytestosterone aromatization by carbon monoxide. *Biochem. Biophys. Res. Commun.* 63: 496-501.
7. Osathanondh, R., Canick, J.A., Ryan, K.J., Tulchinsky, D. (1976) Placental sulfatase deficiency: a case study. *J. Clin. Endocrinol. Metab.* 43: 208-214.
8. Canick, J.A., Ryan, K.J. (1976) Cytochrome P-450 and the aromatization of 16α -hydroxytestosterone and androstenedione by human placental microsomes. *Mol. Cell. Endocrinol.* 6: 105-115.
9. Canick, J.A., Vaccaro, D.E., Ryan, K.J., Leeman, S.E. (1977) The aromatization of androgens by primary monolayer cultures of fetal rat hypothalamus. *Endocrinology* 100: 250-253.
10. Barbieri, R.L., Canick, J.A., Ryan, K.J. (1977) Danazol inhibits steroidogenesis in rat testis in vitro. *Endocrinology* 101: 1676-1682.
11. Barbieri, R.L., Canick, J.A., Makris, A., Todd, R.B., Davies, I.J., Ryan, K.J. (1977) Danazol inhibits steroidogenesis. *Fertil. Steril.* 28: 809-813.
12. Canick, J.A., Ryan, K.J. (1978) Properties of the aromatase system associated with the mitochondrial fraction of human placenta. *Steroids* 32: 499-509.
13. Barbieri, R.L., Canick, J.A., Ryan, K.J. (1978) Estrogen 2-hydroxylase: activity in rat tissues. *Steroids* 32: 529-538.
14. Canick, J.A., Makris, Gunsalus, G.L., Ryan, K.J. (1979) Testicular aromatization in immature rats: localization and stimulation after gonadotropin administration in vivo. *Endocrinology* 104: 285-288.
15. Barbieri, R.L., Osathanondh, R., Canick, J.A., Stillman, R.J., Ryan, K.J. (1980) Danazol inhibits human adrenal 21- and 11β -hydroxylation in vitro. *Steroids* 35: 285-288.
16. Frisch, R.E., Canick, J.A., Tulchinsky, D. (1980) Human fatty marrow aromatizes androgen to estrogen. *J. Clin. Endocrinol. Metab.* 51: 394-396.
17. Callard, G.V., Canick, J.A., Pudney, J.F. (1980) Estrogen synthesis in Leydig cells: structural-functional correlation in *Necturus* testis. *Biol. Reprod.* 23: 461-479.

18. Barbieri, R.L., Canick, J.A., Ryan, K.J. (1981) High affinity steroid binding to rat testis 17α -hydroxylase and human placental aromatase. *J. Steroid Biochem.* 14: 387-393.
19. Pudney, J., Canick, J.A., Mak, P., Callard, G.V. (1983) The differentiation of Leydig cells, steroidogenesis and the spermatogenic wave in the testis of *Necturus maculosus*. *Gen. Comp. Endocrinol.* 50: 43-66.
20. Baum, M.J., Canick, J.A., Erskine, M.S., Gallagher, C.A., Shim, J.H. (1983) Normal differentiation of masculine sexual behavior in male ferrets despite neonatal inhibition of brain aromatase or 5α -reductase activity. *Neuroendocrinology* 36: 277-284.
21. Suarez-Quian, C.A., Dym, M., Makris, A., Brumbaugh, J., Ryan, K.J., Canick, J.A. (1983) Estrogen synthesis by immature Sertoli cells in vitro. *J. Andrology* 4: 203-209.
22. Barbieri, R.L., Petro, Z., Canick, J.A., Ryan, K.J. (1983) Aromatization of 19-norethindrone to ethinyl estradiol by human placental aromatase. *J. Clin. Endocrinol. Metab.* 57: 299-303.
23. Canick, J.A., Fox, C.D., Callard, G.V. (1984) Studies on cytochrome P-450-dependent microsomal enzymes of testicular androgen and estrogen biosynthesis in a urodele amphibian, *Necturus*. *J. Steroid Biochem.* 21: 237-241.
24. Platia, M.P., Fencl, M.deM., Elkind-Hirsch, K.E., Canick, J.A., Tulchinsky, D. (1984) Estrone sulfatase activity in the human brain and estrone sulfate levels in the normal menstrual cycle. *J. Steroid Biochem.* 21: 237-241.
25. Dunaif, A., Longcope, C., Canick, J., Badger, T., Crowley, W.F. (1985) The effects of the aromatase inhibitor delta-1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease (PCOD). *J. Clin. Endocrinol. Metab.* 60: 773-780.
26. Pudney, J., Canick, J.A., Callard, G.V. (1985) The testis and reproduction in male *Necturus*, with emphasis on *N. Lewisii* (Brimley). *Brimleyana* 10: 53-74.
27. Tobet, S.A., Shim, J.H., Osiecki, S.T., Baum, M.J., Canick, J.A. (1985) Androgen aromatization and 5α -reduction in ferret brain during perinatal development: effects of sex and testosterone manipulation. *Endocrinology* 116: 1869-1877.
28. Pudney, J., Canick, J.A., Clifford, N.M., Knapp, J., Callard, G.V. (1985) Location of enzymes of androgen and estrogen biosynthesis in the testis of the ground squirrel (*Citellus lateralis*). *Biol. Reprod.* 33: 971-980.
29. Tobet, S.A., Baum, M.J., Tang, H.B., Shim, J.H., Canick, J.A. (1985) Aromatase activity in the perinatal rat forebrain: effects of age, sex and intrauterine position. *Develop. Brain Res.* 23: 171-178.
30. Callard, G.V., Pudney, J.A., Mak, P., Canick, J.A. (1985) Stage-dependent changes in steroidogenic enzymes and estrogen receptors during spermatogenesis in the testis of the dogfish, *Squalus acanthias*. *Endocrinology* 117: 1328-1335.
31. Canick, J.A., Vaccaro, D.E., Livingston, E.M., Leeman, S.E., Ryan, K.J., Fox, T.O. (1986) Localization of aromatase and 5α -reductase to neuronal and non-neuronal cells in fetal rat hypothalamus. *Brain Res.* 372: 277-282.
32. Canick, J.A., Tobet, S.A., Baum, M.J., Vaccaro, D.E., Ryan, K.J., Leeman, S.E., Fox, T.O. (1987) Catecholaminergic regulation and the developmental decline in rat hypothalamic aromatase. *Steroids* 50: 509-521.

33. Canick, J.A., Knight, G.J., Palomaki, G.E., Haddow, J.E., Cuckle, H.S., Wald, N.J. (1988) Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br. J. Obstet. Gynaecol. 95: 330-333.
34. Wald, N.J., Cuckle, H.S., Densem, J.W., Canick, J.A., Haddow, J.E., Knight, G.J., Palomaki, G.E. (1988) Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br. J. Obstet. Gynaecol. 95: 334-341.
35. Wald, N.J., Cuckle, H.S., Densem, J.W., Nanchahal, K., Royston, P., Chard, T., Haddow, J.E., Knight, G.J., Palomaki, G.E., Canick, J.A. (1988) Maternal serum screening for Down's syndrome in early pregnancy. Br. Med. J. 297: 883-887.
36. Cuckle, H.S., Wald, N.J., Barkai, G., Fuhrmann, W., Altland, K., Brambati, B., Knight, G., Palomaki, G., Haddow, J.E., Canick, J., (1988) First-trimester biochemical screening for Down syndrome. Lancet ii: 851-852.
37. Osathanondh, R., Canick, J.A., Abell, K.B., Stevens, L.D., Palomaki, G.E., Knight, G.J., Haddow, J.E. (1989) Second trimester screening for trisomy 21. Lancet ii: 52-53 (peer-reviewed letter).
38. Haning, R.V., Hackett, R.J., Boothroid, R.I., Canick, J.A. (1990) Steroid sulphatase activity in the human ovarian corpus luteum, stroma, and follicle: comparison to activity in other tissues and placenta. J. Steroid Biochem. 36: 175-179.
39. Canick, J.A. (1990) Prenatal screening for Down syndrome using maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. J. Clin. Immunoassay 13: 30-33.
40. Cuckle, H.S., Wald, N.J., Densem, J., Royston, P., Knight, G., Haddow, J., Palomaki, G., Canick, J. (1990) The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotropin, progesterone, and dehydroepiandrosterone sulphate levels. Br. J. Obstet. Gynaecol. 97: 272-276.
41. Canick, J.A., Palomaki, G.E., Osathanondh, R. (1990) Prenatal screening for trisomy 18 in the second trimester. Prenat. Diagn. 10: 546-547.
42. Canick, J.A., Knight, G.J., Palomaki, G.E., Haddow, J.E. (1990) Second trimester levels of maternal serum unconjugated estriol and human chorionic gonadotropin in pregnancies affected by fetal anencephaly and open spina bifida. Prenat. Diagn. 10: 733-738.
43. Heyl, P.S., Miller, W.A., Canick, J.A. (1990) Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol. Obstet. Gynecol. 76: 1025-1031.
44. Cuckle, H.S., Wald, N.J., Densem, J.W., Canick, J.A., Abell, K.B. (1991) Second trimester amniotic fluid oestriol, dehydroepiandrosterone sulphate, and human chorionic gonadotropin levels in Down's syndrome pregnancies. Br. J. Obstet. Gynaecol. 98: 1160-1162.
45. Haning, R.V., Hackett, R.J., Canick, J.A. (1992) Steroid sulfatase in the human ovary and placenta: enzyme kinetics and phosphate inhibition. J. Steroid Biochem. 41: 161-165.
46. Oyer, C.E., Canick, J.A. (1992) Maternal serum hCG levels in triploidy: variability and need to consider molar tissue. Prenat. Diagn. 12: 627-629 (peer-reviewed letter).
47. Haddow, J.E., Palomaki, G.E., Knight, G.J., Williams, J., Pulkkinen, A., Canick, J.A., Saller, D.N., Bowers, G.B. (1992) Prenatal screening for Down's syndrome with use of maternal serum markers. N. Engl. J. Med. 327: 588-593.

48. Palomaki, G.E., Knight, G.J., Haddow, J.E., Canick, J.A., Saller, D.N., Panizza, D.S. (1992) Prospective trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. *Prenat. Diagn.* 12: 925--930.
49. Saller, D.N., Canick, J.A., Schwartz, S., Blitzer, M.G. (1992) Multiple marker screening in pregnancies with hydropic and non-hydropic Turner syndrome. *Am. J. Obstet. Gynecol.* 167: 1021-1024.
50. Saller, D.N., Rogers, B.R., Canick, J.A. (1993) Maternal serum biochemical markers in pregnancies with fetal parvovirus B19 infection. *Prenat. Diagn.* 13: 467-471.
51. Neiger, R., Wise, C., Contag, S.A., Tumber, M., Canick, J.A. (1993) First trimester bleeding and pregnancy outcome in gravidas with normal and low folate levels. *Am. J. Perinatol.* 10: 460-462.
52. Saller, D.N., Dailey, J.V., Doyle, D.L., Carr, S.R., Canick, J.A., Rogers., B.R. (1993) Turner syndrome associated with an omphalocele. *Prenat. Diagn.* 13: 424-426.
53. Palomaki, G.E., Knight, G.J., Haddow, J.E., Canick, J.A., Wald, N.J., Kennard, A. (1993) Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin: impact on Down syndrome screening. *Obstet. Gynecol.* 81: 675-678.
54. Saller, D.N., Canick, J.A., Palomaki, G.E., Knight, G.J., Haddow, J.E. (1994) Second trimester maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin levels in pregnancies with ventral wall defects. *Obstet. Gynecol.* 84: 852-855.
55. Rose, N.C., Canick, J.A., Knight, G.J., Pulkkinen, A., Tumber, M.B., Mennuti, M.T., Palomaki, G.E. (1994) Second trimester diurnal variation of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: is it present and does it affect prediction of a patient's risk for fetal Down syndrome? *Prenat. Diagn.* 14: 947-951.
56. Keren, D.F., Canick, J.A., Johnson, M.Z., Schaldenbrand, J.D., Haning, R.V., Hackett, R. (1995) Low maternal serum unconjugated estriol during prenatal screening as an indication of placental steroid sulfatase deficiency and X-linked ichthyosis. *Am.J. Clin. Pathol.* 103: 400-403.
57. Canick, J.A., Kellner, L.H., Saller, D.N., Palomaki, G.E., Walker, R.P., Osathanondh, R. (1995) Second trimester levels of maternal urinary gonadotropin peptide in Down syndrome pregnancy. *Prenat. Diagn.* 15: 739-744.
58. Palomaki, G.E., Haddow, J.E., Knight, G.J., Wald, N.J., Kennard, A., Canick, J.A., Saller, D.N., Blitzer, M.G., Dickerman, L.H., Fisher, R., Hansmann, M., Luthy, D.A., Summers, A.M., Wyatt, P. (1995) Risk-based screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. *Prenat. Diagn.* 15: 713-723.
59. Saller, D.N., Oyer, C.E., Star, J., Canick, J.A. (1996) A normative study of obstetrical complications associated with trisomy 18. *J. Perinatol.* 16: 117-120.
60. Haning, R.V., Canick, J.A., Goldsmith, L.T., Shahinian, K.A., Erinakes, N.J., Weiss, G. (1996) The effect of ovulation induction on the concentration of maternal serum relaxin in twin pregnancies. *Am. J. Obstet. Gynecol.* 174: 227-232.
61. Carpenter, M.W., Canick, J.A., Star, J., Carr, S.R., Burke, M.E., Shahinian, K.A. (1996) Fetal hyperinsulinism at 14-20 weeks and subsequent gestational diabetes. *Obstet. Gynecol.* 87: 89-93.

62. Seifer, D.B., Lambert-Messerlian, G.M., Canick, J.A., Frishman, G.N., Schneyer, A.L. (1996) Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies. *Fertil. Steril.* 65: 667-669.
63. Saller, D.N., Canick, J.A., Oyer, C.E., (1996) The detection of non-immune hydrops through second trimester maternal serum screening. *Prenat. Diagn.* 16: 431-435.
64. Lambert-Messerlian, G.M., Canick, J.A., Palomaki, G.E., Schneyer, A.L. (1996) Second trimester levels of maternal serum inhibin A, total inhibin, α inhibin precursor, and activin in Down syndrome pregnancy. *J. Med. Screening* 3: 58-62.
65. Onda, T., Kitigawa, M., Takeda, O., Sago, H., Kubonoya, K., Iinuma, K., Bradley, L., Canick, J.A., Krasikow, N.E., Ponting, N.R., Grier, R.E. (1996) Triple marker screening in native Japanese women. *Prenat. Diagn.* 16: 713-717.
66. Cuckle, H.S., Canick, J.A., Kellner, L.H., Van Lith, J.M.M., White, I., Helbig, B.R., Rose, N.R., Sehmi, I.K., Jones, R. (1996) Urinary β -core-hCG screening in the first trimester. *Prenat. Diagn.* 16: 1057-1059.
67. Haning, R.V., Tantravahi, U., Zhao, Q., Hackett, R.J., Canick, J.A. (1996) 5α -Reductase 1 and 2 expression and activity in human ovarian follicles, stroma and corpus luteum as compared to neonatal foreskin. *J. Steroid Biochem.* 59: 199-204.
68. Lambert-Messerlian, G.M., Canick, J.A., Palomaki, G.E. (1996) Maternal serum total activin A in pregnancies affected with fetal Down's syndrome. *J. Med. Screening* 3: 217.
69. Star, J., Canick, J.A., Palomaki, G.E., Carpenter, M.W., Saller, D.N., Sung, C.J., Tumber, M.B., Coustan, D.R. (1997) The relationship between second-trimester amniotic fluid insulin and glucose levels and subsequent gestational diabetes. *Prenat. Diagn.* 17: 149-154.
70. Canick, J.A., Abuelo, D.N., Bradley, L.A., Tint, G.S. (1997) Maternal serum marker levels in two pregnancies affected with Smith-Lemli-Opitz syndrome. *Prenat. Diagn.* 17: 187-189.
71. Bradley, L.A., Canick, J.A., Palomaki, G.E., Haddow, J.E. (1997) Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. *Am. J. Obstet. Gynecol.* 176: 531-535.
72. Frishman, G.N., Canick, J.A., Hogan, J.W., Hackett, R., Kellner, L.H., Saller, D.N. (1997) Maternal serum triple marker screening in singleton in vitro fertilization versus naturally conceived pregnancies. *Obstet. Gynecol.* 90: 98-101.
73. Cole, L.A., Kellner, L.H., Isozaki, T., Palomaki, G.E., Iles, R.K., Walker, R.P., Ozaki, M., Canick, J.A. (1997) Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies. *Prenat. Diagn.* 17: 607-614.
74. Lambert-Messerlian, G.M., Steinhoff, M., Zheng, W., Canick, J.A., Seifer, D.B., Schneyer, A.L. (1997) Multiple immunoreactive inhibin proteins in women with epithelial ovarian cancer: Importance of age-specific normal ranges and potential utility of alpha inhibin as a serum marker. *Gynecol. Oncol.* 65: 512-516.
75. Saller, D.N., Canick, J.A., Kellner, L.H., Rose, N.C., Garza, J., French, C.A., Mooney, R.A. (1997) Maternal serum analyte levels in fetal Down syndrome pregnancies due to translocations. *Am. J. Obstet. Gynecol.* 177: 879-881.

76. Kellner, L.H., Canick, J.A., Palomaki, G.E., Neveux, L.M., Saller, D.N., Walker, R.P., Osathanondh, R., Bombard, A.T. (1997) Levels of urinary beta-core fragment, total estriol and the ratio of the two in second trimester screening for Down syndrome. *Prenat. Diagn.* 17: 1135-1141.
77. Lambert-Messerlian, G.M., Canick, J.A., Melegos, D.N., Diamandis, E.P. (1998) Increased concentrations of prostate specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. *Clin. Chem.* 44: 205-208.
78. Canick, J.A., Rish, S. (1997) The accuracy of assigned risks in maternal serum screening. *Prenat. Diagn.* 18: 413-415.
79. Lambert-Messerlian, G.M., Luisi, S., Florio, P., Mazza, V., Canick, J.A., Petraglia, F. (1998) Second trimester levels of maternal serum total activin A and placental inhibin/activin alpha and beta A subunit messenger ribonucleic acids in Down syndrome pregnancy. *Eur. J. Endocrinol.* 138: 425-429.
80. Lambert-Messerlian, G.M., Saller, D.N., Tumber, M.B., French, C.A., Peterson, C.J., Canick, J.A. (1998) Second trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. *Prenat. Diagn.* 18: 1061-1067.
81. Lambert-Messerlian, G.M., Saller, D.N., Tumber, M.B., French, C.A., Peterson, C.J., Canick, J.A. (1999) Second trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18. *Prenat. Diagn.* 19: 476-479.
82. Saller, D.N., Canick, J.A., Blitzer, M.G., Palomaki, G.E., Schwartz, S., Blakemore, K.J., Haddow, J.E. (1999) Second trimester maternal serum analyte levels associated with fetal trisomy 13. *Prenat. Diagn.* 19: 813-816.
83. Silver, H.M., Lambert-Messerlian, G.M., Star, J.A., Hogan, J., Canick, J.A. (1999) Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic and non-proteinuric gestationally hypertensive pregnancy. *Am. J. Obstet. Gynecol.* 180: 1131-1137.
84. Carpenter, M.W., Canick, J.A., Star, J., Shellum, C., Somers, M. (1999) A high-sensitivity assay for amniotic fluid insulin:characterization in 14-20 week specimens. *Obstet. Gynecol.* 94: 778-782.
85. Wald, N.J., White, N., Canick, J.A. (1999) Serum markers for Down's syndrome in women who have had *in vitro* fertilisation: implications for antenatal screening. *Br. J. Obstet. Gynaecol.* 106: 1304-1306.
86. Cuckle, H.S., Canick, J.A., Kellner, L.H. (1999) Collaborative study of maternal urine β -core human chorionic gonadotropin screening for Down syndrome. *Prenat. Diagn.* 19: 911-917.
87. Phipps, M.G., Hogan, J.W., Peipert, J.F., Lambert-Messerlian, G.M., Canick, J.A., Seifer, D.B. (2000) Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. *Obstet. Gynecol.* 95: 227-231.
88. Malone, F., D'Alton, M.E., Berkowitz, R., Canick, J.A. (2000) First trimester screening for aneuploidy: research or standard of care? *Am. J. Obstet. Gynecol.* 182: 490-496.
89. Rausch, D., Lambert-Messerlian, G.M., Canick, J.A. (2000) Participation in maternal serum screening following screen positive results in a previous pregnancy. *J. Med. Screen.* 7: 4-6.
90. Lambert-Messerlian, G.M., Silver, H.M., Petraglia, F., Luisi, S., Pezzani, I., Maybruck, W.M., Hogge, W.A., Hanley-Yanez, K., Roberts, J.M., Neveux, L.M., Canick, J.A. (2000) Second trimester levels of

maternal serum inhibin A and human chorionic gonadotropin predict preeclampsia in the third trimester of pregnancy. J.Soc. Gynecol. Invest. 7: 170-174.

91. Lambert-Messerlian, G.M., Palomaki, G.E., Canick, J.A. (2000) Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects. Prenat. Diagn. 20: 680-682.
92. Goodwin, K.M., Sweeney, P.J., Lambert-Messerlian, G.M., Canick, J.A. (2000) Supraphysiological maternal serum levels of inhibin A in an apparently healthy pregnancy. Prenat. Diagn. 20: 1015-1017.
93. Yamamoto, H., Lambert-Messerlian, G.M., Silver, H.M., Kudo, R., Kellner, L.H., Canick, J.A. (2001) Maternal serum levels of type I and type III procollagen peptides in preeclamptic pregnancy. J. Matern. Fetal Med. 10: 40-43.
94. Yasuhi I., Hogan J.W., Canick J., Sosa M.B., Carpenter M.W. (2001) Midpregnancy serum C-peptide concentration and subsequent pregnancy-induced hypertension. Diabetes Care 24: 743-747.
95. Silver, H.M., Lambert-Messerlian, G.M., Reis, F.M., DiBlasio, A.M., Petraglia, F., Canick, J.A. (2002) The mechanism of increased maternal serum total activin A and inhibin A in preeclampsia. J. Soc. Gynecol. Invest. 9: 308-312.
96. Lee, T., LeShane E.S., Messerlian, G.M., Canick, J.A., Farina, A., Heber, W.W., Carpenter, M.W., Bianchi.D.W. (2002) Down syndrome and cell-free fetal DNA in archived maternal serum. Am. J. Obstet. Gynecol. 187: 1217-1221.
97. Thirunavukarasu, P.P., Lambert-Messerlian, G., Robertson, D.M., Dawson, G., Canick, J., Wallace, E.M. (2002) Molecular weight forms of inhibin A, inhibin B and pro- α C in maternal serum , amniotic fluid and placental extracts of normal and Down syndrome pregnancies. Prenat. Diagn. 22: 1086-1092.
98. Wataganara, T., LeShane, E.S., Farina, A., Messerlian, G.M., Lee, T., Canick, J.A., Bianchi, D.W. (2003) Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum. Genet. 112: 204-208.
99. Farina, A., LeShane, E., Lambert-Messerlian, G.M., Canick, J.A., Lee, T., Neveux, L.M., Palomaki, G.E., Bianchi, D.W. (2003) Performance of cell-free fetal DNA as a second trimester maternal serum marker of Down syndrome pregnancy. Clin. Chem. 49: 239-242.
100. Plevyak, M.P., Lambert-Messerlian, G.M., Farina, A., Groome, N.P., Canick, J.A., Silver, H.M. (2003) Concentrations of serum total activin A and inhibin A in preterm and term labor patients: a cross-sectional study. J. Soc. Gynecol. Investig. 10: 231-236.
101. Florio, P., Lambert-Messerlian, G., Severi, F.M., Buonocore, G., Canick, J.A., Petraglia, F. (2004) Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. Prenat. Diagn. 24: 574-575.
102. Lambert-Messerlian, G.M., Halliday, J., Williams, J., Cain, R., Msall, M.E., Palomaki, G.E., Canick, J.A. (2004) Effect of folic acid fortification on prevalence of neural tube defects in Rhode Island. J. Med. Screen. 11: 106-107.
103. Lambert-Messerlian, G.M., Pinar, H., Laprade, E., Tantravahi, U., Schneyer, A., Canick, J.A. (2004) Inhibins and activins in human fetal abnormalities. Mol. Cell. Endocrinol. 225:101-108.

104. Lambert-Messerlian, G.M., Canick, J.A. (2004) Placenta growth factor levels in second trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia. *Prenat. Diagn.* 24:876-880.
105. Dugoff, L., Hobbins, J.C., Malone, F.D., Vidaver, J., Sullivan, L., Canick, J.A., Lambert-Messerlian, G.M., Porter, T.F., Luthy, D.A., Comstock, C.H., Saade, G., Eddleman, K., Merkatz, I.R., Craig, S.D., Timor-Trisch, I.E., Carr, S.R., Wolfe, H.M., D'Alton, M.E. (2005) Quad screen as a predictor of adverse pregnancy outcome. *Obstet. Gynecol.* 106:260-267.
106. Malone, F.D., Ball, R.H., Nyberg, D.A., Comstock, C.H., Saade, G.R., Berkowitz, R.L., Gross, S.J., Dugoff, L., Craig, S.D., Timor-Trisch, I.E., Carr, S.R., Wolfe, H.M., Dukes, K., Canick, J.A., Bianchi, D.W., D'Alton, M.E. (2005) First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome. *Obstet. Gynecol.* 106:288-294.
107. Lambert-Messerlian, G., Pinar, H., Rubin, L.P., De Paepe ME, Tantravahi U, Steinhoff MM, Russell M, Canick, J.A. (2005) Second-trimester maternal serum markers in twin pregnancy with complete mole: report of 2 cases. *Pediatr. Dev. Pathol.* 8:230-234.
108. Pan, P.D., Peter, I., Lambert-Messerlian, G.M., Canick, J.A., Bianchi, D.W., Johnson, K.L. (2005) Cell-free fetal DNA levels in pregnancies conceived by IVF. *Hum. Reprod.* 20: 3152-3156.
109. Lambert-Messerlian, G.M., Keren, D.F., Raphtis, C.S., Byberg, K., Canick, J.A. (2005) Apparently low maternal serum inhibin A levels in second-trimester screening. *Prenat. Diagn.* 25: 967-968.
110. Malone, F.D., Canick, J.A., Ball, R.H., Nyberg, D.A., Comstock, C.H., Bukowski, R., Berkowitz, R.L., Gross, S.J., Dugoff, L., Craig, S.D., Timor-Tritsch, I.E., Carr, S.R., Wolfe, H.M., Dukes, K., Bianchi, D.W., Rudnicka, A.R., Hackshaw, A.K., Lambert-Messerlian, G., Wald, N.J., D'Alton, M.E. (2005) First-trimester or second-trimester screening, or both, for Down's syndrome. *N. Engl. J. Med.* 353: 2001-2011.
111. Lambert-Messerlian, G.M., Eklund, E.E., Malone, F.D., Palomaki, G.E., Canick, J.A., D'Alton, M.E. (2006) Stability of first- and second-trimester serum markers after storage and shipment. *Prenat. Diagn.* 26: 17-21.
112. Farina A, Lambert-Messerlian GM, Canick JA, Banzola I, Carletti A, Concu M, Tempesta A, Gabrielli S, Morano D, Rizzo N. Total activin A in maternal blood as a marker of preterm delivery in low-risk asymptomatic patients. *Prenat. Diagn.* 2006; 26:277-281.
113. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick J, Malone F, Ball R, Comstock C, Nyberg D, Saade G, Eddleman K, Gross S, Craig S, Timor I, Carr S, Wolfe H, D'Alton M. First and second trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study. *Prenat. Diagn.* 2006 (in press).

OTHER PEER REVIEWED PUBLICATIONS

1. Wald, N.J., Cuckle, H.S., Densem, J.W., Nanchahal, K., Royston, P., Chard, T., Haddow, J.E., Knight, G.J., Palomaki, G.E., Canick, J.A. (1989) Serum screening for Down's syndrome. *Br. Med. J.* 298: 50 (letter).
2. Wald, N.J., Densem, J.W., Haddow, J.E., Palomaki, G.E., Knight, G.J., Canick, J.A. (1991) Prenatal screening for Down's syndrome. *Br. Med. J.* 303: 715 (letter).

3. Wald, N.J., Kennard, A., Watt, H., Haddow, J.E., Palomaki, G.E., Knight, G.J., Canick, J.A. (1995) Decision-analysis and screening for Down's syndrome - testing should be in all women. *Br. Med. J.* 311: 1372-1373 (letter).
4. Cole, L., Isozaki, T., Palomaki, G., Canick, J. (1996) Detection of beta-core fragment in second trimester Down's syndrome pregnancies. *Early Hum. Dev.* 47 (Suppl.): S47-48.
5. Canick, J.A. (1998) Current state of second trimester screening for Down's syndrome. *J. Med. Screen.* 5: 113-114. [editorial]
6. Malone, F.D., D'Alton, M.E., Berkowitz, R.L., Canick, J.A. (2000) Reply to Letters to the Editor. *Am. J. Obstet. Gynecol.* 183: 1591-1592.
7. Wald, N.J., Canick, J.A. (2002) Seeking other disorders within antenatal serum screening programmes for Down's syndrome. Case example: Trisomy 18. *J. Med. Screen.* 9:145-146 [editorial]
8. Canick, J.A. (2003) Safety first: Choices in antenatal screening for Down's syndrome. *J. Med. Screen.* 10: 55 [editorial]

BOOKS

1. Clinics in Laboratory Medicine: Prenatal Testing (2003) Canick, J.A., Lambert-Messerlian, G.M., eds., Saunders, Philadelphia.

BOOK CHAPTERS

1. Canick, J.A., Tobet, S.A., Shim, J.H., Baum, M.J. (1984) Pattern of aromatase and 5 alpha-reductase in the brain of the developing ferret and rat. In: Metabolism of Hormonal Steroids in the Neuroendocrine Structures (F. Celotti, F. Naftolin, L. Martini, eds.), Raven Press, New York, pp. 15-20.
3. Singer, D.B., Plotz, R.D., Canick, J.A. (1985) Laboratory evaluation of the ambulatory gynecology patient. In: Ambulatory Gynecology (D.H. Nichols, J.R. Evrard, eds.), Harper and Row, Philadelphia, pp. 223-240.
3. Canick, J.A., Barbieri, R.L. (1990) The effect of smoking on hormone levels *in vivo* and steroid hormone biosynthesis *in vitro*. In: Smoking and Hormone Related Disorders (N. Wald, J. Baron, eds.) Oxford Univ. Press, Oxford, pp. 208-216.
4. Canick, J.A. (1990) Oestrogens and smoking-related disease: theoretical considerations. In: Smoking and Hormone Related Disorders (N. Wald, J. Baron, eds.) Oxford Univ. Press, Oxford, pp. 219-221.
5. Canick, J.A., Saller, D.N. (1993) Maternal serum screening for aneuploidy and open fetal defects. In: Obstetrics and Gynecology Clinics of North America (K. Blakemore, ed.), W.B. Saunders Co., Philadelphia, Vol. 20(3), pp. 443-454.
6. Saller, D.N., Canick, J.A. (1996) Maternal serum screening for fetal trisomy 21: clinical aspects. *Clin. Obstet. Gynecol.* 39: 783-792.
7. Saller, D.N., Canick, J.A. (1996) Maternal serum screening for fetal trisomy 21: the detection of other pathologies. *Clin. Obstet. Gynecol.* 39: 793-800.

8. Canick, J.A., (1998) Methodology for the study of metabolism: analysis of proteins, peptides, and small molecules. In: Principles of Perinatal-Neonatal Metabolism, 2nd Ed. (R.M. Cowett, ed.) Springer-Verlag, New York, pp. 27-39.
9. Canick, J.A. (1998) α -fetoprotein and triple screening. In: Encyclopedia of Reproduction, Vol. 2 (E. Knobil and J. Neill, eds.) Academic Press, New York, pp. 351-357.
10. Lambert-Messerlian, G.M., Canick, J.A. (1999) Endocrine assays for multiple marker screening: hCG, CG subunits, inhibin, and free estriol. In: Clinics in Perinatology (J. Strauss and W.L. Miller, eds.), Saunders, Philadelphia, pp. 963-981.
11. Carpenter, M.W., Canick, J.A., (2000) Amniotic fluid insulin and C-peptide in normal and diabetic pregnancy. In: Amniotic Fluid, (K.A. Rao, ed.), Prism Books Pvt Ltd., Bangalore, pp. 191-196.
12. Canick, J.A., Kellner, L.H., Bombard, A.T. (2003) Prenatal screening for open neural tube defects. In: Clinics in Laboratory Medicine: Prenatal Testing, Canick, J.A., Lambert-Messerlian, G.M., eds., Saunders, Philadelphia, pp. 385-394.
13. Canick, J.A., Saller, D.N., Lambert-Messerlian, G.M. (2003) Prenatal screening for Down syndrome: Current and future methods. In: Clinics in Laboratory Medicine: Prenatal Testing, Canick, J.A., Lambert-Messerlian, G.M., eds., Saunders, Philadelphia, pp. 395-411
14. MacRae, A.R., Canick, J.A. (2004) Maternal prenatal screening for fetal defects. In: Current Clinical Pathology: Handbook of Clinical Laboratory Testing During Pregnancy. Gronowski, A.M., ed., Humana Press, pp. 71-137.
15. Milunsky, A., Canick, J.A. (2004) Maternal serum screening for neural tube and other defects. In: Genetic Disorders of the Fetus, 5th Ed., Milunsky, A., ed., Johns Hopkins Univ. Press, Baltimore, pp. 719-794.

ARTICLES IN REVIEW JOURNALS

1. Canick, J.A., Carpenter, M.W., Bowers, G.B. (1985) Alpha-fetoprotein in testing for fetal integrity: Its use and implications. *Laboratory Management* 23: 23-36.
2. Canick, J.A., Knight, G.J. (1990) Is multiple marker screening for Down syndrome useful? Screening performance is improved. *Perspect. Genet. Counseling* 12(2): 1-4.
3. Canick, J.A., Bowers, G.B. (1991) Enhanced prenatal screening for Down syndrome using multiple biochemical markers. *The Genetic Resource* 6: 5-9.
4. Canick, J.A., Knight, G.J. (1992) Multiple-marker screening for fetal Down syndrome. *Contemporary Ob/Gyn* 36: 25-42.
5. Canick, J.A., Saller, D.N. (1993) Screening biochimico prenatale per la sindrome de Turner e le trisomie dei cromosomi sessuali. *The Ligand Quarterly* 12: 308-311.
6. Canick, J.A., Saller, D.N. (1997) Antenatal screening for Down's syndrome. *Gynaecology Forum* 2: 19-22.
7. Canick, J.A., Carr, S. (1998) Screening for birth defects: integrating laboratory evaluation, genetic counseling, and clinical intervention. *Medicine & Health/Rhode Island* 81: 122-126.

8. Canick, J.A., Kellner, L.H., Cole, L.A., Cuckle, H.S. (1999) Urinary analyte screening: a noninvasive detection method for Down syndrome? *Molecular Medicine Today* 5: 68-73.
9. Canick, J.A., Kellner, L.H. (1999) Maternal serum markers in screening for Down syndrome in the first trimester. In: Seminars in Perinatology, Vol. 23(5) F. Malone, ed., Saunders, pp. 359-368.
10. Lambert-Messerlian, G.M., Canick, J.A. (2002) An update on prenatal screening for Down syndrome. *Medicine & Health/Rhode Island* 85:362-365.
11. Canick, J.A. (2004) New choices in prenatal screening for Down syndrome: programmatic and laboratory considerations. *Clin. Lab. News* 30: 12-15.
12. Lambert-Messerlian, G.M., Canick, J.A. (2004) Clinical application of inhibin A measurement: prenatal serum screening for Down syndrome. In: Seminars in Reproductive Medicine. Vol. 22, No. 3 Castracane, V.D., Lambert-Messerlian, G.M., eds., Thieme, New York, pp. 235-242.
13. Canick, J.A., MacRae, A.R. (2005) Second trimester serum markers. In: Seminars in Perinatology, Vol. 29, No. 4, Reddy, U.M., Mennuti, M.T., eds., Elsevier, pp. 203-208.
14. Canick, J.A. (2005) New choices in prenatal screening for Down syndrome. In: OBG Management. Vol. 17(12), pp. 38-47.
15. Palomaki, G.E., Canick, J.A., Lambert-Messerlian, G.M. (2006) A summary analysis of Down syndrome markers in the late first trimester. In: Advances in Clinical Chemistry. G. Makowski, Ed., Academic Press (in press)

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. Canick, J.A., Lambert-Messerlian, G.M., Farina, A. (2002) General principles of second trimester maternal serum screening for Down syndrome. UpToDate, Clinical Reference Library (on-line and on CD-ROM), review updated annually (current version 14.2, 2006).
2. Canick, J.A., Lambert-Messerlian, G.M., Farina, A. (2002) Second trimester maternal serum screening for Down syndrome: clinical recommendations. UpToDate, Clinical Reference Library (on-line and on CD-ROM), review updated annually (current version 14.2, 2006).
3. Canick, J.A., Lambert-Messerlian, G.M., Farina, A. (2002) Pregnancy complications predicted by second trimester maternal serum screening. UpToDate, Clinical Reference Library (on-line and on CD-ROM), review updated annually (current version 14.2, 2006).
4. Canick, J.A., Lambert-Messerlian, G.M., Farina, A. (2002) First trimester screening for Down syndrome. UpToDate, Clinical Reference Library (on-line and on CD-ROM), review updated annually (current version 14.2, 2006).
5. Canick, J.A., Lambert-Messerlian, G.M. (2002) Patient information: Prenatal detection of Down syndrome. UpToDate, Clinical Reference Library (on-line and on CD-ROM), review updated annually (current version 14.2, 2006).
6. D'Alton, M.E., Canick, J.A., Malone, F.D. (2003) First-trimester screening for aneuploidy. ACOG Update, a continuing medical education program. Audio tape and printed text. Vol. 28, No. 11, Publication date: May 2003.